Testing a New Targeted Therapy ETX-19477 to Treat Advanced Breast, Colorectal Endometrial, Ovarian or Pancreatic Cancer in People with a BRCA2 Mutation (ERADIC8)

About the Study

Researchers are studying whether the targeted therapy ETX-19477 is a safe and effective treatment option for people with a BRCA2 mutation who have been diagnosed with metastatic or advanced breast, colorectal, endometrial, ovarian or pancreatic cancer. ETX-19477 is a type of drug known as a PARG inhibitor. It works by interfering with cancer cells' ability to repair damage to their DNA. Researchers hope this may slow tumor growth or cause cancer cells to die.The goal of this study is to find the safest and most effective dose of ETX-19477 for treating metastatic or advanced cancers. 

What the Study Involves

There is one arm to this study.  

• All people enrolled in this study will receive the study drug. 
• Participants will take ETX-19477 by mouth once daily.
• Participants will stay on this treatment until their cancer gets worse or they have side effects that require stopping the medication.

People may be eligible if all of the following apply:

• They are age 18 or older.
• They have been diagnosed with advanced or metastatic breast, colorectal, endometrial, ovarian or pancreatic cancer.
• They have a BRCA2 mutation.
• Their cancer has come back or gotten worse after standard treatment or they cannot tolerate available treatments.
• Their cancer can be measured using imaging or other tests.
• They have a life expectancy of at least 3 months.

Visit Clinicaltrials.gov for the full eligibility listing. 

People may not be eligible if they:

• Have untreated or worsening cancer that has spread to the brain or spinal fluid. People whose brain metastases have been treated and are stable may still qualify.
• Have significant heart problems or uncontrolled heart disease.
• Have an active serious infection, such as uncontrolled hepatitis B, hepatitis C, tuberculosis, or another significant infection. 
• Have serious liver, kidney, gastrointestinal, or pancreatic disease that could affect safety or the body's ability to absorb the study drug.
• Have received radiation therapy too recently before starting the study.
• Are taking certain medications that may interact with ETX-19477 or affect how the body processes medications.
• Are receiving another investigational treatment or recently participated in another clinical trial.
• Have another cancer that required treatment within the past two years, with some exceptions for certain early-stage cancers.

Visit Clinicaltrials.gov for the full eligibility listing.